Table: begin end state 1 29 signal peptide 30 51 non-cytoplasmic 52 72 transmembrane 73 83 cytoplasmic 84 106 transmembrane 107 112 non-cytoplasmic 113 131 transmembrane 132 137 cytoplasmic 138 161 transmembrane 162 181 non-cytoplasmic 182 207 transmembrane 208 218 cytoplasmic 219 239 transmembrane 240 244 non-cytoplasmic 245 263 transmembrane 264 270 cytoplasmic 271 293 transmembrane 294 300 non-cytoplasmic 301 321 transmembrane 322 344 cytoplasmic 345 366 transmembrane 367 386 non-cytoplasmic 387 407 transmembrane 408 418 cytoplasmic 419 438 transmembrane 439 443 non-cytoplasmic 444 465 transmembrane 466 473 cytoplasmic 474 497 transmembrane 498 516 non-cytoplasmic 517 537 transmembrane 538 561 cytoplasmic 562 589 transmembrane 590 603 non-cytoplasmic 604 623 transmembrane 624 629 cytoplasmic 630 651 transmembrane 652 658 non-cytoplasmic
Input: >AZOBR_RS17950 FitnessBrowser__azobra:AZOBR_RS17950 MAVNRILLWSGLALAAAALSAWQVAGHAAAPSMPLPPDAAWLDGVILYHSVLPRIAVALV AGAALGLSGLLLQRVLRNPLAEPSTLGVSAGAQLALTLGMLYAPALMDHAREGVALAGGL AAVGLILAMTWRRGLEPVAVVLAGMMVALTATMGSAALILANGEYLFSIFLWGGGALAQQ SWGPTLTIAVRLLIGVGAAVLLMRPLAILGLDDASARSLGVALNATRFGVIGVAVWLAAS VTAEVGVIGFVGLAAPALAHLSGARTQGQRLVAAPLIGALLLWLTDGLVQLLAGVDGERV PTGAATALLGGPLLLWLLPRLRMFEWPSLNSRPAPSRRSLHPYRLIALFAVLGAVAVGLA LTVGYGPGGWTLSTGPLLDTLLGWRGPRVAVAAAAGAMLAAAGMLLQRVTANPLASPEIL GVGTGAGVGLTAALFLVAAPGFGVQLAASAAGAVLTLAAMLALSLRAGFGPERLLLAGIA MSALCSAVLTAVIATGTPQAFALLRWLSGSTNEAGPGDAWFCIGVAVLLLATLPLTAKWL EILPLGDVTAQAVGLPVRRCRVLLVLLAGLLTAAAALFVGPLSFIGLIAPHLARLAGLGR PLQQGIGAVLIGAGLMVVSDWLARTVAFPYQLPLGLFAALLAGPYLVWLLGRSNARTP
Or try the official Phobius web server, which has a different display
Reference: Advantages of combined transmembrane topology and signal peptide prediction - the Phobius web server